Last reviewed · How we verify
A Randomized, Placebo-controlled, Double-blind, Crossover, Single-dose Exposure Study to Evaluate the Early Bronchodilating Effect of FlutiForm 100/10 µg HFA pMDI and FlutiForm 250/10 µg HFA pMDI, Compared to Placebo in Adult Subjects With Mild to Moderate Asthma
The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.
Details
| Lead sponsor | SkyePharma AG |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 39 |
| Start date | 2008-09 |
| Completion | 2008-10 |
Conditions
- Mild to Moderate Asthma
Interventions
- fluticasone propionate, formoterol fumarate
- fluticasone propionate, formoterol fumarate
- fluticasone propionate, formoterol fumarate
Primary outcomes
- Change from baseline FEV1 to post study drug dosing FEV1 — 3 minutes
Countries
United States